相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
Christopher T. Petersen et al.
FRONTIERS IN ONCOLOGY (2019)
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Noam Ponde et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Vadim Le Joncour et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2
Morse Faria et al.
ANTIBODIES (2019)
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Noam Ponde et al.
CANCER TREATMENT REVIEWS (2018)
Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine
Wei Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Developing anti-HER2 vaccines: Breast cancer experience
Aydah Al-Awadhi et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Fate of Antibody-Drug Conjugates in Cancer Cells
Cecile Chalouni et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Paula Salmikangas et al.
PHARMACEUTICAL RESEARCH (2018)
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
Pamela A. Trail et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists
Lars Mecklenburg
TOXICOLOGIC PATHOLOGY (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Lea Lowenfeld et al.
CLINICAL CANCER RESEARCH (2017)
Human CD3+T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells
Rusheni Munisvaradass et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives
R. L. B. Costa et al.
CANCER TREATMENT REVIEWS (2017)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
Carla Rios-Luci et al.
CANCER RESEARCH (2017)
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
John M. Lambert et al.
ADVANCES IN THERAPY (2017)
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells
Sherly Mardiana et al.
CANCER RESEARCH (2017)
Trastuzumab in the Treatment of Breast Cancer
Sofia Maximiano et al.
BIODRUGS (2016)
Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
Soumaya Labidi et al.
BREAST CARE (2016)
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
Elizabeth A. Mittendorf et al.
ONCOTARGET (2016)
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Hilde Almasbak et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
Romualdo Barroso-Sousa et al.
ECANCERMEDICALSCIENCE (2016)
Engineering CAR-T cells: Design concepts
Shivani Srivastava et al.
TRENDS IN IMMUNOLOGY (2015)
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way
Nuket Eliyatkin et al.
JOURNAL OF BREAST HEALTH (2015)
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
Tomofumi Osako et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
P95 HER2 fragments and breast cancer outcome
Deniz Tural et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
DNA vaccine for cancer immunotherapy
Benjamin Yang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Meili Sun et al.
BREAST CANCER RESEARCH (2014)
Pertuzumab: new hope for patients with HER2-positive breast cancer
M. Capelan et al.
ANNALS OF ONCOLOGY (2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
Ceyhan Ceran et al.
BMC CANCER (2012)
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Elizabeth A. Mittendorf et al.
CANCER (2012)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
The GP2 peptide: A HER2/neu-based breast cancer vaccine
Kevin S. Clive et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
The Role of Genetics in IBS
Yuri A. Saito
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2011)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
Laura M. Hodges et al.
PHARMACOGENETICS AND GENOMICS (2011)
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Gabriel L. Fiszman et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2011)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database
Carlos S. Vallejos et al.
CLINICAL BREAST CANCER (2010)
Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Karly P. Garnock-Jones et al.
DRUGS (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
Reiki Nishimura et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2010)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence - From US Military Cancer Institute clinical trials group study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
HER-2-positive metastatic breast cancer: trastuzumab and beyond
Giulio Metro et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Basal-like breast cancer: A critical review
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer
John W. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Molecular classification of breast cancer: Limitations and potential
Lajos Pusztai et al.
ONCOLOGIST (2006)
Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients
Anne E. Kayl et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2006)
Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?
JD Brenton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer
MH Kershaw et al.
JOURNAL OF IMMUNOLOGY (2004)
Biologic and therapeutic role of HER2 in cancer
S Ménard et al.
ONCOGENE (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Immunization with a HER-2/neu helper peptide generates HER-2/neu CD8 T-cell immunity in cancer patients
KL Knutson et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
分享论文
